Welcome to our dedicated page for Allarity SEC filings (Ticker: ALLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allarity Therapeutics, Inc. (NASDAQ: ALLR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Phase 2 clinical-stage biopharmaceutical company focused on stenoparib and its DRP® companion diagnostic platform, Allarity uses SEC reports to communicate material events, financing transactions, and periodic financial information to investors.
Among the key documents available are Form 8-K current reports, where Allarity has disclosed events such as FDA Fast Track designation for stenoparib in advanced ovarian cancer, new clinical data presentations from its Phase 2 ovarian cancer trial, conference participation on biomarkers and precision medicine, licensing and laboratory services agreements for DRP® algorithms, and private placement securities purchase agreements. Filings like NT 10-Q (Form 12b-25) explain timing of quarterly reports and provide context on the status of financial statement reviews.
Through Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of each document, helping users quickly understand disclosures related to clinical development, capital structure, registration rights, and governance changes. Real-time updates from EDGAR ensure that new Allarity filings are added as they become available, including quarterly and annual reports when filed, as well as any future Forms 10-K, 10-Q, or additional 8-Ks.
Investors researching ALLR can use this page to review how Allarity describes its business focus on stenoparib and DRP®, track unregistered equity offerings and registration rights agreements, and monitor other material events reported under SEC rules. The combination of original documents and AI-generated overviews is intended to make complex regulatory language more accessible while preserving the underlying source information.
Allarity Therapeutics, Inc. filed Amendment No. 1 to its registration statement (File No. 333-293420) on April 24, 2026 as an exhibits-only amendment to furnish an updated auditor consent. The Amendment updates Exhibit 23.1 and includes the facing page, Item 16, signature page, exhibit index, and filed exhibits; the prospectus is unchanged.
Allarity Therapeutics, Inc. filed a current report describing two new scientific posters on its lead drug candidate stenoparib and its DRP® companion diagnostic, presented at the AACR Annual Meeting 2026 in San Diego.
One poster links higher stenoparib DRP® scores with enhanced overall survival in a phase 2 trial in advanced, recurrent ovarian cancer, supporting DRP-based patient selection. The second poster shows stenoparib’s dual PARP/tankyrase mechanism can modulate the WNT/β-catenin signaling pathway and inhibit growth of colorectal cancer cell lines at clinically relevant concentrations.
The company emphasizes stenoparib’s potential in colorectal and ovarian cancers and highlights ongoing phase 2 trials in ovarian cancer and small cell lung cancer, alongside broader plans to use its DRP® platform to identify patients most likely to benefit from treatment.
Allarity Therapeutics, Inc. has filed a proxy statement for its 2026 Annual Meeting of Stockholders to be held virtually on June 26, 2026. The meeting (record date May 7, 2026) asks shareholders to vote on director election, ratification of Wolf & Company as auditors, an amendment to increase the 2021 Equity Incentive Plan reserve from 1,521,990 to 2,021,990 shares, a non-binding say-on-pay vote, Nasdaq 20% Rule approval related to an equity line providing up to $6,000,000, a certificate amendment to permit officer exculpation (requiring 66-2/3% of outstanding shares to approve), and an adjournment proposal. The proxy explains voting mechanics for virtual attendance, quorum rules (one-third quorum) and broker voting treatments for each proposal.
Allarity Therapeutics reported 2025 results showing its first revenue and a sharply reduced loss as it advanced cancer drug stenoparib. Revenue reached $320 thousand from licensing agreements, compared to no revenue in 2024.
Net loss attributable to shareholders narrowed to $11.2 million, or $0.78 per share, versus $25.1 million, or $15.65 per share, reflecting lower operating costs. General and administrative expenses fell to $6.3 million from $11.4 million, while R&D rose modestly to $6.6 million. Cash was $14.7 million and total liabilities declined to $8.4 million as of December 31, 2025.
Allarity Therapeutics, Inc. files its annual report describing a refocused business built around stenoparib, a dual PARP/tankyrase inhibitor for difficult-to-treat cancers. The company’s proprietary DRP® companion diagnostic platform is used to select patients most likely to respond, aiming for smaller, more effective trials.
Management has terminated other programs to conserve capital and concentrate on stenoparib and its DRP®. Stenoparib is in Phase 2 ovarian cancer studies and a separate VA-funded trial in relapsed small cell lung cancer, and received FDA fast-track designation for advanced recurrent ovarian cancer.
The report highlights extensive DRP® intellectual property, multiple partnerships, and a license with Eisai that includes development milestones, royalties and a potential buy-back option. Allarity is an emerging growth and smaller reporting company, disclosing substantial funding needs and continued reliance on Nasdaq listing compliance.
Allarity Therapeutics, Inc. announced it has closed a $20 million non-convertible debt financing with Streeterville Capital, structured via two promissory notes of $10,930,000 and $10,000,000, providing approximately $20 million in net proceeds.
The company expects this financing to extend its cash runway into the summer of 2028 and primarily use the funds to advance stenoparib in advanced ovarian cancer, including completing its Phase 2 trial, preparing for an FDA End-of-Phase-2 meeting, and supporting pivotal development and commercialization plans, as well as further developing its DRP companion diagnostic platform.
Allarity Therapeutics, Inc. entered into a financing arrangement with Streeterville Capital through two new promissory notes. The company issued an A-1 Note with an original principal amount of $10,930,000 and a secured B Note with an original principal amount of $10,000,000, both maturing 18 months after issuance.
After closing, Streeterville paid $10,000,000 to Allarity, and another $10,000,000 was placed in a controlled deposit account owned by a new wholly owned subsidiary, ALLR Holdings, LLC. The A-1 Note has a 9.00% annual interest rate and includes a $900,000 original issue discount and $30,000 of expenses, while the B Note bears 5.00% annual interest.
Beginning six months after issuance, the lender may redeem up to $250,000 plus accrued interest per month, payable in cash. The notes are secured by the controlled account, a guaranty from the subsidiary, and a pledge of all membership interests in the subsidiary, and include covenants restricting additional variable-price or secured financings and certain subsidiary activities. Trigger and default events can increase the outstanding balance and raise the interest rate up to 15% per year.
Allarity Therapeutics, Inc. announced that the first patients have been dosed with stenoparib in combination with temozolomide in a U.S. Department of Veterans Affairs–funded investigator-initiated Phase 2 trial for relapsed small cell lung cancer, an area described as having high unmet medical need.
The trial is fully funded through the VA’s Special Emphasis Panel on Precision Oncology and is open for enrollment across 11 VA medical centers in the United States. Allarity highlights stenoparib’s dual PARP and WNT pathway inhibition, its favorable safety profile compared with earlier PARP inhibitors, and its ability to cross the blood-brain barrier as potential advantages in this setting.
Allarity Therapeutics is registering 255,103 shares of common stock for resale by a single selling stockholder. These shares were issued on December 23, 2025 as “Additional Shares” in a private placement at $0.98 per share, which previously generated approximately $250,000 in gross proceeds for the company.
The resale registration is purely for the stockholder’s benefit; Allarity will not receive any proceeds when these shares are sold. As context, 16,080,980 shares of common stock were outstanding as of February 11, 2026, and the Nasdaq closing price that day was $0.90 per share.
In earlier tranches of the private placement, Allarity sold 760,916 shares and 801,584 pre-funded warrants for roughly $2.5 million in gross proceeds and may sell up to $6.0 million of additional stock over time under a separate equity line agreement. The company remains a clinical-stage oncology business focused on stenoparib and operates as an emerging growth and smaller reporting company, highlighting ongoing capital needs and potential future dilution.
Allarity Therapeutics, Inc. reported that enrollment has opened for a new Phase 2 clinical trial. The study evaluates a combination of stenoparib and temozolomide to treat patients with recurrent small cell lung cancer.
The company released a press statement about this development, which is included as an exhibit to the report and incorporated by reference.